Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer

Yeon Chun Jae, Nagalakshmi Nadiminty, Ok Lee Soo, Sergio A. Onate, Wei Lou, Allen C Gao

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Prevention trials showed that selenium reduced prostate cancer incidence by 50%, establishing selenium as a promising chemopreventive agent for prostate cancer. Selenium inhibited human prostate cancer cell growth, blocked cell cycle progression at multiple transition points, and induced apoptotic cell death. Previous studies showed a novel mechanism of selenium anticancer action in which selenium markedly reduces androgen signaling and androgen receptor (AR) - mediated gene expression, including prostate-specific antigen (PSA), in human prostate cancer cells. The molecular mechanisms of selenium-mediated down-regulation of AR signaling are not clear. In this study, a systemic approach was taken to examine the modification of androgen signaling by selenium in human prostate cancer cells. In addition to reduced AR mRNA expression, selenium was found to initially increase the stability of AR mRNA within 6 hours while decreasing the stability of AR mRNA after 8 hours. Selenium increased AR protein degradation and reduced AR nuclear localization. Scatchard analysis indicated that selenium did not affect ligand binding to AR in LNCaP cells. Chromatin immunoprecipitation analyses showed that DHT increased the recruitment of AR and coactivators, such as SRC-1 and TIF-2, to the promoter of the PSA gene, and that recruitment was greatly diminished in the presence of 5 μmol/L selenium. On the other hand, selenium enhanced the recruitment of corepressors, such as SMRT, to the promoter of the PSA gene. Taken together, these results suggest that selenium disrupts AR signaling at multiple stages, including AR mRNA expression, mRNA stability, protein degradation, nuclear translocation, and recruitment of coregulators.

Original languageEnglish (US)
Pages (from-to)913-918
Number of pages6
JournalMolecular Cancer Therapeutics
Volume5
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Androgen Receptors
Selenium
Prostatic Neoplasms
Down-Regulation
Messenger RNA
Prostate-Specific Antigen
Androgens
Proteolysis
Co-Repressor Proteins
Chromatin Immunoprecipitation
RNA Stability
Genes
Cell Cycle
Cell Death

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. / Jae, Yeon Chun; Nadiminty, Nagalakshmi; Soo, Ok Lee; Onate, Sergio A.; Lou, Wei; Gao, Allen C.

In: Molecular Cancer Therapeutics, Vol. 5, No. 4, 04.2006, p. 913-918.

Research output: Contribution to journalArticle

Jae, Yeon Chun ; Nadiminty, Nagalakshmi ; Soo, Ok Lee ; Onate, Sergio A. ; Lou, Wei ; Gao, Allen C. / Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. In: Molecular Cancer Therapeutics. 2006 ; Vol. 5, No. 4. pp. 913-918.
@article{d06fb69fdc0d4516a20f5a3d77788f6a,
title = "Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer",
abstract = "Prevention trials showed that selenium reduced prostate cancer incidence by 50{\%}, establishing selenium as a promising chemopreventive agent for prostate cancer. Selenium inhibited human prostate cancer cell growth, blocked cell cycle progression at multiple transition points, and induced apoptotic cell death. Previous studies showed a novel mechanism of selenium anticancer action in which selenium markedly reduces androgen signaling and androgen receptor (AR) - mediated gene expression, including prostate-specific antigen (PSA), in human prostate cancer cells. The molecular mechanisms of selenium-mediated down-regulation of AR signaling are not clear. In this study, a systemic approach was taken to examine the modification of androgen signaling by selenium in human prostate cancer cells. In addition to reduced AR mRNA expression, selenium was found to initially increase the stability of AR mRNA within 6 hours while decreasing the stability of AR mRNA after 8 hours. Selenium increased AR protein degradation and reduced AR nuclear localization. Scatchard analysis indicated that selenium did not affect ligand binding to AR in LNCaP cells. Chromatin immunoprecipitation analyses showed that DHT increased the recruitment of AR and coactivators, such as SRC-1 and TIF-2, to the promoter of the PSA gene, and that recruitment was greatly diminished in the presence of 5 μmol/L selenium. On the other hand, selenium enhanced the recruitment of corepressors, such as SMRT, to the promoter of the PSA gene. Taken together, these results suggest that selenium disrupts AR signaling at multiple stages, including AR mRNA expression, mRNA stability, protein degradation, nuclear translocation, and recruitment of coregulators.",
author = "Jae, {Yeon Chun} and Nagalakshmi Nadiminty and Soo, {Ok Lee} and Onate, {Sergio A.} and Wei Lou and Gao, {Allen C}",
year = "2006",
month = "4",
doi = "10.1158/1535-7163.MCT-05-0389",
language = "English (US)",
volume = "5",
pages = "913--918",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer

AU - Jae, Yeon Chun

AU - Nadiminty, Nagalakshmi

AU - Soo, Ok Lee

AU - Onate, Sergio A.

AU - Lou, Wei

AU - Gao, Allen C

PY - 2006/4

Y1 - 2006/4

N2 - Prevention trials showed that selenium reduced prostate cancer incidence by 50%, establishing selenium as a promising chemopreventive agent for prostate cancer. Selenium inhibited human prostate cancer cell growth, blocked cell cycle progression at multiple transition points, and induced apoptotic cell death. Previous studies showed a novel mechanism of selenium anticancer action in which selenium markedly reduces androgen signaling and androgen receptor (AR) - mediated gene expression, including prostate-specific antigen (PSA), in human prostate cancer cells. The molecular mechanisms of selenium-mediated down-regulation of AR signaling are not clear. In this study, a systemic approach was taken to examine the modification of androgen signaling by selenium in human prostate cancer cells. In addition to reduced AR mRNA expression, selenium was found to initially increase the stability of AR mRNA within 6 hours while decreasing the stability of AR mRNA after 8 hours. Selenium increased AR protein degradation and reduced AR nuclear localization. Scatchard analysis indicated that selenium did not affect ligand binding to AR in LNCaP cells. Chromatin immunoprecipitation analyses showed that DHT increased the recruitment of AR and coactivators, such as SRC-1 and TIF-2, to the promoter of the PSA gene, and that recruitment was greatly diminished in the presence of 5 μmol/L selenium. On the other hand, selenium enhanced the recruitment of corepressors, such as SMRT, to the promoter of the PSA gene. Taken together, these results suggest that selenium disrupts AR signaling at multiple stages, including AR mRNA expression, mRNA stability, protein degradation, nuclear translocation, and recruitment of coregulators.

AB - Prevention trials showed that selenium reduced prostate cancer incidence by 50%, establishing selenium as a promising chemopreventive agent for prostate cancer. Selenium inhibited human prostate cancer cell growth, blocked cell cycle progression at multiple transition points, and induced apoptotic cell death. Previous studies showed a novel mechanism of selenium anticancer action in which selenium markedly reduces androgen signaling and androgen receptor (AR) - mediated gene expression, including prostate-specific antigen (PSA), in human prostate cancer cells. The molecular mechanisms of selenium-mediated down-regulation of AR signaling are not clear. In this study, a systemic approach was taken to examine the modification of androgen signaling by selenium in human prostate cancer cells. In addition to reduced AR mRNA expression, selenium was found to initially increase the stability of AR mRNA within 6 hours while decreasing the stability of AR mRNA after 8 hours. Selenium increased AR protein degradation and reduced AR nuclear localization. Scatchard analysis indicated that selenium did not affect ligand binding to AR in LNCaP cells. Chromatin immunoprecipitation analyses showed that DHT increased the recruitment of AR and coactivators, such as SRC-1 and TIF-2, to the promoter of the PSA gene, and that recruitment was greatly diminished in the presence of 5 μmol/L selenium. On the other hand, selenium enhanced the recruitment of corepressors, such as SMRT, to the promoter of the PSA gene. Taken together, these results suggest that selenium disrupts AR signaling at multiple stages, including AR mRNA expression, mRNA stability, protein degradation, nuclear translocation, and recruitment of coregulators.

UR - http://www.scopus.com/inward/record.url?scp=33646562820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646562820&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0389

DO - 10.1158/1535-7163.MCT-05-0389

M3 - Article

C2 - 16648561

AN - SCOPUS:33646562820

VL - 5

SP - 913

EP - 918

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -